Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Other Non-Current Assets (2021 - 2024)

Historic Other Non-Current Assets for China SXT Pharmaceuticals (SXTC) over the last 6 years, with Q3 2024 value amounting to $8.5 million.

  • China SXT Pharmaceuticals' Other Non-Current Assets changed N/A to $8.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $8.5 million, marking a year-over-year change of. This contributed to the annual value of $8.3 million for FY2024, which is 488.48% down from last year.
  • According to the latest figures from Q3 2024, China SXT Pharmaceuticals' Other Non-Current Assets is $8.5 million.
  • Over the past 5 years, China SXT Pharmaceuticals' Other Non-Current Assets peaked at $9.5 million during Q1 2022, and registered a low of $2.9 million during Q3 2020.
  • Its 5-year average for Other Non-Current Assets is $8.1 million, with a median of $8.6 million in 2023.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Other Non-Current Assets skyrocketed by 22590.1% in 2021, and later tumbled by 942.01% in 2022.
  • China SXT Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $2.9 million in 2020, then surged by 225.9% to $9.3 million in 2021, then decreased by 9.42% to $8.4 million in 2022, then rose by 3.58% to $8.7 million in 2023, then dropped by 2.14% to $8.5 million in 2024.
  • Its last three reported values are $8.5 million in Q3 2024, $8.3 million for Q1 2024, and $8.7 million during Q1 2023.